According to Kind Consumer, the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the company’s Voke nicotine inhaler for general sale. The company said that the license is “for use to relieve and/or prevent craving and nicotine withdrawal symptoms associated with tobacco dependence.”
Kind Consumer Chief Medical Officer Chris Moyses commented, “We are pleased to announce that the Voke Inhaler has been licensed in the UK as a medicinal product after a detailed review process by the MHRA. It is a great achievement for the team to have successfully navigated the process to marketing authorization during which we have satisfied all questions raised by the MHRA. The technology contains no electronics, heat or combustion and will rival e-cigarettes and nicotine-replacement therapies when launched.”
CEO Paul Triniman said, “Achieving the first authorization for the Voke Inhaler as a licensed medicine is a major milestone for the company. The Voke Inhaler will be commercialized by Nicoventures Ltd., now engaged in ensuring that automated manufacturing capacity will be in place, as well as the marketing plans to bring this advance in nicotine technology to smokers.”
In a separate press release, Nicoventures, a subsidiary of British American Tobacco, said, “Nicoventures congratulates Kind Consumer on obtaining the initial medicinal product licence for Voke, which has been designed for smokers who want to reduce, replace or stop smoking. This is a major step forward in BAT’s commitment to offering smokers a choice of satisfying safer alternative products and validates the technology behind this invention.”
Read the Kind Consumer press release.
Read the Nicoventures press release.
